SmartPeptide
Start Free
MuscleNot compoundable — no approved indicationLimited human evidence

CJC-1295 / Ipamorelin

Growth-hormone secretagogue combination studied for stimulating endogenous GH pulses in research contexts.

Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.

What the research shows

Both compounds have pharmacology data in healthy adults showing increased endogenous GH pulses without affecting prolactin or cortisol much. Some PK/PD trials are published.

What's still experimental

Outcome trials (body composition, recovery, longevity) are sparse and mostly small. Long-term safety of repeated GH stimulation is not well established.

Anecdotal / community reports

Body-composition and sleep-quality reports are common; many users overlook baseline lifestyle and training.

Anecdotal reports are NOT scientific evidence. They reflect personal experience and may not generalize.

FDA approval status

Source: openFDA + DailyMed (NIH/NLM)
No FDA-approved drug label exists for “CJC-1295 / Ipamorelin”. This peptide is not currently approved by the FDA as a finished pharmaceutical product. Any commercial product claiming FDA approval should be treated with suspicion.

Doses studied in research

Source: Published clinical trial

What published trials tested or FDA-approved labels specify. Reporting research facts — not a SmartPeptide recommendation.

Community-anecdotal range — NOT a SmartPeptide recommendation

The doses below are aggregated from research-peptide community forums (Reddit, biohacker discussions). They are NOT supported by clinical trials, NOT FDA-approved, and NOT a SmartPeptide recommendation. Source purity, dose accuracy, and user-reported outcomes are unverifiable. We display this only because the information is publicly available elsewhere — visitors should absolutely consult a licensed clinician familiar with experimental peptides before any use.

Community-anecdotal — not evidence-basedResearch-peptide community forums + 503A clinic protocols
Indication studied: Community-discussed for GH/IGF-1 stimulation (no FDA approval for adult anti-aging use)
Typical
100µg
1-3x daily · subcutaneous

Each peptide; CJC-1295 100µg + Ipamorelin 100µg blend per injection commonly discussed

Open calculator
Maximum
300µg
1-3x daily · subcutaneous

Higher anecdotal range

Open calculator

Notes from the source: Adult use is off-label. Some 503A clinics prescribe in this range; SmartPeptide cannot verify which protocols are clinically appropriate. Long-term effects on glucose tolerance and theoretical cancer signaling are not characterized.

Important framing: The numbers above are what published trials tested or what FDA-approved labels specify. They are NOT a SmartPeptide recommendation for you. Trial doses come paired with screening, monitoring, and clinician oversight. Always consult a licensed clinician before any peptide use.

How clinicians typically protocol this

Third-party reference · not our recommendation

Dosing phases, cycle lengths, and administration timing as listed in a compounding-pharmacy clinician reference guide. Shown so you can see what a real protocol looks like — and bring informed questions to a licensed clinician.

Third-party protocol referenceCompounding-pharmacy clinician protocol reference (Nov 2025)

Dose numbers, frequencies, and cycle lengths in this panel are extracted from a clinician-facing reference protocol distributed by a US-based compounding pharmacy in November 2025. SmartPeptide has paraphrased all descriptive text and adds no endorsement. Always consult a licensed clinician.

Growth Hormone

GHRH analog + selective GHRP blend — dual-pathway endogenous GH release.

Protocol phases

Typical AM
300–500 µg5 days/week
subcutaneous

pre-workout, fasted

Typical PM
300–500 µg5 days/week
subcutaneous

at bedtime

Cycle length

8–10 weeks on / 4–8 weeks off.

Administration timing

Carbs and fat blunt GH release. AM fasted or PM bedtime dosing preferred.

Reported side effects
Injection-site reactionsRare headache or flushing
Reconstitution calculator Storage & reconstitution guide
Not medical advice. SmartPeptide does not prescribe, diagnose, or treat. The protocol above reproduces dose figures from a third-party clinician reference so you can see what compounding-pharmacy guidance typically looks like — it is not a recommendation for you, and it has not been validated against peer-reviewed dose-ranging trials. Many of these compounds are not FDA-approved for human use. Work with a licensed clinician familiar with peptide therapy before considering anything here.

FDA enforcement & recalls

Live · openFDA Drug Enforcement API
No FDA enforcement actions (recalls, market withdrawals, safety alerts) on record for “CJC-1295 / Ipamorelin”. This is the expected baseline for most peptides — the absence of recalls does NOT imply general safety, only that no formal FDA enforcement has been initiated against approved formulations.

Mechanism & targets

ChEMBL · UniProt · Open Targets

Molecule (ChEMBL)

View on ChEMBL
Formula
C18H12F5N3O

Live research

PubMed · ClinicalTrials.gov · Europe PMC · OpenAlex
PubMed papers
77
total
Human studies
0
MeSH: humans
Clinical trials
0
published
Active trials
0
4 total registered

Clinical trials (ClinicalTrials.gov)

All trials for "CJC-1295 OR ipamorelin"

Europe PMC — 181 additional records

Includes EU/UK studies and PubMed Central full-text articles. Often surfaces research weeks before PubMed indexes it.

Human clinical evidence

Semantic Scholar · AI TLDRs · influence-ranked
Semantic Scholar API is currently rate-limited.

Human-study summaries for “CJC-1295 OR ipamorelin” are available on Semantic Scholar but the shared free-tier API quota is exhausted right now. Try refreshing in a few minutes, or check the PubMed and Europe PMC panels above for the same literature.

Research funding & verification

NIH RePORTER · CrossRef DOI registry

Publication landscape

CrossRef · DOI registry
Indexed works (CrossRef)
47,494
all DOIs registered
Retracted papers
0
no retractions on record
Top funders of indexed research
  • National Institutes of Health576 works
  • National Natural Science Foundation of China529 works
  • Canadian Institutes of Health Research232 works
  • National Science Foundation173 works
  • Heart and Stroke Foundation of Canada81 works
  • American Heart Association75 works

Funder diversity is a credibility signal. Research concentrated in a single drug company's funding warrants more scrutiny than research funded across NIH, charities, and academic grants.

Preprints — cutting edge

bioRxiv · medRxiv · via Europe PMC

Preprints have NOT been peer-reviewed. They are early research shared by authors before formal validation. Treat findings as preliminary.

Showing 4 of 4 preprints indexed by Europe PMC.

Known risks

Carries risks similar to elevated GH (insulin resistance, edema). Not approved for general use.

Reported side effects

Water retention, injection-site irritation, headaches.

FDA adverse event reports (FAERS)

Updated quarterly by FDA
Reports filed
3
FAERS, all years
Serious reports
3
100% of reports

Most-reported reactions

  • Abdominal Pain Upper
    1
  • Acute Kidney Injury
    1
  • Blood Glucose Increased
    1
  • Blood Potassium Decreased
    1
  • Drug Hypersensitivity
    1
  • Dysphagia
    1
  • Dyspnoea
    1
  • Feeling Abnormal
    1
  • Heart Rate Increased
    1
  • Hepatic Function Abnormal
    1

Counts from FDA Adverse Event Reporting System (FAERS). Voluntary reports — they show what was reported, not whether the drug caused the event. Many reports lack confirmation. FAERS docs

What requires medical supervision

Carries risks consistent with elevated GH (insulin resistance, edema, joint discomfort). Should be supervised; baseline IGF-1 and glycemic monitoring are reasonable.

Questions for your clinician

  • Should we baseline IGF-1, fasting glucose, and HbA1c?
  • How long is one cycle and how do we de-escalate?
  • What signs of insulin resistance should I watch for?

Editorially curated references

Discussions about CJC-1295 / Ipamorelin

Start a discussion
No discussions yet — be the first. Share what you've learned, what worked, what didn't, or a study you want translated into plain English.
See all CJC-1295 / Ipamorelin discussions Native, moderated, no buying or selling